<DOC>
	<DOCNO>NCT01323712</DOCNO>
	<brief_summary>Patients Chronic Kidney Disease ( CKD ) upto 3.5 time likely die disease heart blood vessel ( Cardiovascular Disease-CVD ) . Vitamin D insufficiency common CKD associate CVD . Animal study show improvement heart size function Vitamin D therapy , although evidence human lack . The propose study test oral Vitamin D treatment , deficient CKD patient , improve heart enlargement function . With proposed change investigator expect reduce CVD death patient CKD .</brief_summary>
	<brief_title>Vitamin D Supplementation Cardiac Hypertrophy Chronic Kidney Disease ( CKD )</brief_title>
	<detailed_description>Impact Vitamin D supplementation Cardiac Hypertrophy Function Chronic Kidney Disease Patients- A randomise placebo control trial . 1 . Lay summary : Patients Chronic Kidney Disease ( CKD ) 3.5 time likely die disease heart blood vessel ( Cardiovascular Disease-CVD ) . Vitamin D insufficiency common CKD associate CVD . Animal study show improvement heart size function Vitamin D therapy , although evidence human lack . The propose study test oral Vitamin D treatment , deficient CKD patient , improve heart enlargement function . With proposed change investigator expect reduce CVD death patient CKD . 2 . Abstract propose investigation : Traditional risk factor inadequately explain disproportionate increase CV risk CKD . Hypovitaminosis D common CKD associate increase CV mortality . In animal experiment , vitamin D reduces LV mass ( LVM ) improve systolic function . In dialysis patient , observational study show vitamin D therapy reduces CV mortality improve diastolic function . However , benefit native vitamin D repletion cardiac structure function investigate human . The investigator propose test randomise , placebo-controlled trial , 40 week oral Colecalciferol , predialysis CKD patient , result reduction LV mass improvement systolic/diastolic function along cardiac extracellular matrix composition . Currently , NICE recommend routine measurement vitamin D CKD patient . If effective setting , outcome trial prove inexpensive easily administer therapy routinely prescribed prevent morbidity mortality . 3 . Background project pilot data : ( ) CVD CKD : CV death rate 3.4 time high patient CKD compare general population ( 1 ) . The investigator others demonstrate graded relationship CV event death decline renal function ( 2 ) . Traditional risk factor partially explain elevated risk . This highlights importance non-traditional risk factor inflammation , oxidative stress , vitamin D deficiency modifiable CV risk factor CKD . ( ii ) Vitamin D deficiency general population CKD Hypovitaminosis D common general population . A study Thadhani 's group 15,088 adult show prevalence Vitamin D insufficiency 40-80 % US general population ( 3 ) . CKD patient increase risk hypovitaminosis D. In group 145 non-dialysis CKD patient south London , see 85 % prevalence Vitamin D insufficiency [ 25 hydroxy vitamin D ( 25 ( OH ) D ) &lt; 75 nmol/L ] , include 32 % deficiency [ 25 ( OH ) D &lt; 37.5nmol/L ] , significantly high risk among Afro-Caribbeans ' south-Asians ' ( 4 ) . ( iii ) Hypovitaminosis D CV disease : Cross sectional study show independent association low 25 ( OH ) D CV mortality ( 5 ; 6 ) . In dialysis population , observational study Thadhani et al show increase early CV mortality patient low 25 ( OH ) D level ( OR=1.9 ) . Vitamin D supplementation associate well survival dialysis ( OR=0.6 ) ( 7 ) . ( iv ) Vitamin D improve cardiac function morphology : The Vitamin D endocrine system ubiquitous human tissue , include myocardium vascular endothelium . There mount evidence animal study Vitamin D directly affect cardiac function structure genomic action cardiac myocytes . Vitamin D knockout mouse show increase cardiomyocyte hypertrophy , cardiac fibrosis heart weight ( 8 ) . More importantly , treatment vitamin D spontaneously hypertensive heart failure rat wild type mouse show attenuate cardiac hypertrophy fibrosis , modulate cardiac myocyte contractility , respectively ( 9 ; 10 ) . In animal model Dahl salt sensitive rat treat active vitamin D 6 week , Thadhani 's group demonstrate reduction heart weight , LVM , posterior wall thickness increase fractional shortening . There significant reduction plasma BNP renin level rat fed high salt ( HS ) along Vitamin D , compare rat feed HS diet alone . There difference BP two group , thus reaffirm direct action vitamin D cardiac morphology function , opposed haemodynamic effect . Most importantly , also demonstrate improvement diastolic function , reduction septal posterior wall thickness small observational study haemodialysis patient , treat active vitamin D , suggest finding animal model replicate human ( 11 ) . Moreover , intravenous Vitamin D administration group haemodialysis patient secondary hyperparathyroidism associate significant reduction LVM Index ( 178 ±73 165±61 g/m2 ) transthoracic echocardiogram 15 week ( 12 ) . However , study thus far investigated effect native vitamin D repletion cardiac structure function , randomize , double-blind , placebo-controlled trial predialysis CKD . ( v ) Vitamin D cardiac fibrosis : Recent evidence use gadolinium-enhanced cardiac magnetic resonance ( CMR ) , suggest cardiac fibrosis predominant feature uremic cardiomyopathy ( 13 ) . Animal study demonstrate important role vitamin D maintain extracellular matrix ( ECM ) composition heart . In vitamin D receptor knockout mouse model mark increase cardiac fibrosis , relate abnormal expression collagenase ( 14 ) . Studies Diez 's group hypertensive heart disease subject identify reliable serum biomarker reflect type 1 collagen synthesis human heart- Carboxy-terminal propeptide procollagen type 1 ( PICP ) ( 15 ) . Serum PICP along free Matrix metalloproteinases 1 ( MMP-1 ) free Tissue inhibitor metalloproteinases 1 ( TIMP 1 ) , marker collagen degradation accurately reflect collagen metabolism heart ( 15 ) . PICP release 1:1 ratio synthesis type 1 collagen , precursor procollagen type 1 . Furthermore , peripheral serum PICP accurately reflect amount collagen type 1 fibre heart ( 16 ) therefore use monitor effect treatment collagen content heart ( 17 ) . However , study thus far show effect vitamin D therapy change ECM composition within human heart . ( vi ) Abnormal LV size systolic diastolic dysfunction pre dialysis CKD patient : In group 18 consecutive stable stage 4 5 CKD patient , deem suitable renal transplantation , investigator see significant increase LVM , interventricular septal ( IVS ) diameter posterior wall diameter systolic diastolic dysfunction ; use combination Transthoracic Cardiac Tissue Doppler Imaging ( TDI ) echocardiography , compare normal control . ( 5 ) Original Hypothesis The investigator propose 40 week treatment oral Colecalciferol improve cardiac structure function predialysis CKD patient , consequence improvement cardiac ECM composition turnover . The investigator plan address central hypothesis follow specific aim : ( ) Specific Aim 1 : To determine effect oral Colecalciferol therapy leave ventricular mass measure CMR image . The investigator expect 10g reduction LVM CMR active treatment group compare control . ( ii ) Specific Aim 2 : To determine effect oral Colecalciferol therapy cardiac systolic function cardiac TDI diastolic function transthoracic echocardiography . Systolic function measure improvement average longitudinal peak systolic strain rate ( SR ) longitudinal end systolic strain ( S ) assess base , mid wall apex IVS , lateral , inferior anterior wall cardiac TDI . Improvement diastolic function measure early ( peak E ) late ( peak A ) , trans-mitral flow annulus motion , isovolumetric relaxation time ( IVRT ) deceleration time ( DT ) transthoracic echocardiogram . These parameter test randomised placebo control trial involve 25 patient arm . 25 hydroxy vitamin D3 [ 25 ( OH ) D ] use proposal , CKD stage 3-4 patient would expect adequate store 1 α-hydroxylase enzyme convert 25 ( OH ) D active 1,25 ( OH ) 2 D. The investigator measure level 25 hydroxy colecalciferol ensure adequate repletion . Colecalciferol show safe effective give dose ( 18 ; 19 ) . To examine improvement ECM composition turnover investigator demonstrate reduction cardiac collagen content measure decrease serum PICP Tissue inhibitor metalloproteinases 1 ( TIMP1 ) increase serum Matrix metalloproteinase 1 ( MMP1 ) . PICP correct eGFR bone alkPO4 . MMP1/TIMP1 ratio use measure collagen degradation . Cardiac function pre post therapy , also assess measure plasma N-Terminal proBNP ( NT proBNP ) . Furthermore , biobank whole cell , mRNA DNA , blood urine create future analysis novel gene biological pathway . ( 6 ) Experimental detail design propose project ( ) Study Population : Vitamin D naive patient recruit general nephrology outpatient clinic St. George 's , Guy 's Kingston hospital . Patients 25 ( OH ) D deficiency [ ( 25 ( OH ) D &lt; 37.5 nmol/L ] ( Kidney Disease Outcomes Quality Initiative guideline ) ACEi/ARB therapy , enrol . Cardiac recruitment criterion leave ventricular mass index ( LVMI ) 80-160 g/m2 female 100-160 g/m2 male ( figure correspond upper tertile normal LV mass index ( LVMI ) TTE base Framingham Heart study ( 20 ) .and LVMI 1SD mean value observe CKD3-4 , base CREATE study ) ( 21 ) ( ii ) Patient randomization , blind follow-up : A clinical trial pharmacist oversee randomisation two equal group comparison , blind dispense medication . The stage trial summarise : - 50 patient 25 ( OH ) D level &lt; 37.5 nmol/L recruit . Patient demographic , anthropometric data pertinent clinical history would obtain upon enrollment . Blood collect calcium , phosphate , parathyroid hormone level , bone alkPO4 , high sensitivity C reactive protein ( hsCRP ) . Biomarkers cardiac fibrosis ( serum PICP ) , ECM turnover ( MMP1 TIMP1 ) cardiac function ( plasma NT proBNP ) measure . Transthoracic Echocardiography perform baseline fulfill recruitment criterion diastolic function . Cardiac TDI function CMR perform baseline systolic function LVM , respectively . - Patients randomise 2 equal group receive 4 directly observed oral dos 150,000 IU 50 ml vegetable oil colecalciferol ( Martindale , UK ) 0 , 10 , 20 30 week match placebo . - At 40 week blood sample collect repeat haematology , biochemistry biomarkers collagen synthesis metabolism mention . Changes LV geometry function re-measured use CMR , Transthoracic cardiac TDI echocardiography , respectively . Changes pre post treatment measurement compare active placebo group . All patient continue follow general nephrology clinic trial subsequently upon trial completion . ( iv ) CMR protocol : All subject image 1.5T Philips Intera MRI Scanner dedicate 32 channel cardiac coil . MRI protocol include plan scan , SENSE reference scan , interactive scan identify 4 chamber , 2 chamber long axis short axis geometry heart . Breath hold Steady State Free Procession 4 chamber , 2 chamber short axis stack ( 1.5mm , 1.5mm , 10mm ) cine ( 30 cardiac phase ) acquire . Ventricular mass calculate use viewforum work station ( Philips Healthcare ) delineate diastolic leave ventricular endocardial epicardial border ( figure 2 ) . ( v ) Cardiac Tissue Doppler Imaging Transthoracic Echocardiography : Cardiac TDI record longitudinal deformation . Data obtain septum , lateral , anterior inferior wall use narrow sector ( typically 120 ) . Longitudinal S SR calculate computation area 10 mm . SR S average 3 cardiac cycle analyse use dedicate software ( SPEQLE , Univ . Leuven ) ( figure 3 ) . The intra- inter- observer variability approach le 10 % ( 22 ) . Data obtain parasternal apical view use GE Vivid 7 scanner . LV volume measure use Teichhloz formula . Diastolic function assess previously describe group ( 17 ) . Global radial function assess endocardial mid-wall fractional shortening . All measurement perform use Echo-Pac ( GE ) workstation average 3 individual measure . ( vi ) Analysis Biomarkers Inflammation , Cardiac fibrosis Cardiac Function : : Chronic inflammation quantify serum level high sensitivity C-reactive protein ( hsCRP ) use chemiluminescent immunometric assay ( Immulite® 2500 ) 0,20 40 week . Serum sample store -700 C batch analyse PICP ( RIA- Framos Diagnostica ) , MMP1 TIMP 1 ( ELISA- Amersham ) University Pamplona Plasma NT proBNP measure Elecsys® proBNP immunoassay Roche Elecsys® 1010 immunoassay analyzer baseline study completion . ( vii ) Potential confounders : Haemoglobin maintain 10-13gm % . Use Erythropoietin stimulate agent , dose/frequency iron replacement blood transfusion document . Office blood pressure per BHS guideline document vitamin D administration stage . Changes anti-hypertensive medication follow-up period note . In addition follow parameter assess 0 , 20 40 week : - Plasma Aldosterone/renin activity ratio ; - Pulse wave velocity , Central Arterial Pressure Augmentation Index ( SphygmoCor Pulse Wave Velocity system ) ; - Serum calcium x phosphate product ( &lt; 5 mmol/L ) ; - Urinary protein-creatinine ratio , sodium fractional excretion phosphate ; - Serum FGF-23 . ( viii ) Creation Biobank 10ml EDTA sample cell 3x3 ml tempus tube mRNA PBMC/whole blood collect week 0 , 20 40 week creation biobank Kings college London ( Guy 's Campus ) future analysis novel gene biological pathway . ( ix ) Recruitment retention trial participant Planning preparation trial would conduct first 6 week . 120 CKD patients/week see three hospital site . 30 % patient diabetic 60 % patient GFR &lt; 45 mL/min/1.73m2 . The investigator estimate vitamin D deficiency 35 % base pilot study . Recruitment 50 week . The total duration trial 102 week . A timeline propose study describe figure 3 . ( 7 ) Power calculation statistical analysis The interstudy variability CMR LV mass use protocol similar , report 2.8 % 4.8 % SD 8.4g ( 23 ) . To demonstrate 10g improvement LV mass active treatment group , investigator would need 19 patient [ α= 0.05 Power=95 % ] . Accounting dropout rate 30 % , investigator recruit 25 patient group . Comparisons continuous variable perform use independent sample t-test active treatment placebo group . ( 8 ) Expected value result The investigator confident study adequately power show 10 gm change LVM , use MR scan Reza Rezavi 's laboratory , exist ; similarly change systolic function use echocardiogram expert laboratory St Georges . The investigator also able examine role fibrosis LVH systolic dysfunction measure biomarkers Javier Diez 's laboratory . A large CKD patient population St George 's , Guy 's Kingston Hospitals facilitate recruitment . Figure 3 : Timeline express week show planning , recruitment anticipate randomization 50 patient 25 ( OH ) vitamin D level &lt; 37.5 nmol/L . Cardiac magnetic resonance , Echocardiography , marker cardiac fibrosis measure randomization study completion . CMR- Cardiac magnetic resonance , TDI- Tissue Doppler imaging , TTE- Transthoracic Echocardiography . Analysis report finding take place 96-102 week . ( 9 ) Potential problem alternative strategy : - Impact potential confounders minimise strict entry criterion follow-up protocol . A 30 % attrition rate allow sample size calculation accommodate change patient ' clinical status may account observed change cardiac measurement , rapid decline renal function , MI death trial follow-up , pre-emptive kidney transplantation , CaxP product &gt; 5mmol/L , Hb &lt; 10 &gt; 13gm % persistent high office BP ( &gt; 150/90mmHg ) . - Although patient pilot study young , investigator expect proportionate improvement parameter trial participant well . - The investigator conscious improvement LV function morphology previously show vitamin D therapy human subject . However , evidence genomic effect vitamin D cardiac myocytes , extracellular matrix myocardial contractility well establish animal study . Most importantly , study explores novel anti-fibrotic mechanism vitamin D therapy human , could provide proof principle use vitamin D disease state autoimmune disorder .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hypertrophy</mesh_term>
	<mesh_term>Cardiomegaly</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>50 adult ( 1875 year old ) patient estimate GFR 1545 ml/min/1.73 m2 ( CKD stage 3b 4 ) ACE inhibitor and/or ARB therapy recruit . The following patient exclude trial : patient diabetes mellitus Hb &lt; 10gm % EPO serum calcium &gt; 2.55 mmol/L know malignancy patient vitamin D supplementation heart failure ( ejection fraction &lt; 40 pro NT BNP &gt; 500 pg/ml uncontrolled hypertension ( BP &gt; 150/90 mmHg ) patient AV fistula dialysis access significant valvular heart disease condition may influence collagen metabolism recent ( &lt; 6months ) surgery trauma fibrotic disease active inflammatory condition history myocardial infarction and/or Troponin T &gt; 0.5</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>CKD</keyword>
	<keyword>LV mass</keyword>
	<keyword>Vitamin D</keyword>
	<keyword>LV function</keyword>
</DOC>